1 results match your criteria: "Cell Therapeutics and Haemostaseology LMU University Hospital[Affiliation]"
Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade.
Hemasphere
February 2024
Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology LMU University Hospital, LMU Munich Munich Germany.
Article Synopsis
- CD19-directed immunotherapy is key for treating B-cell precursor acute lymphoblastic leukemia (BCP-ALL), leading to better outcomes and lower toxicity, but challenges like therapy resistance and short remissions persist.
- Researchers tested a new CD19 antibody (CD19-DE) and a modified CD47 antibody (Hu5F9-IgG2σ) to enhance its effectiveness, especially in cases resistant to CD19 treatment.
- The combination therapy showed significant potential in improving therapeutic responses in various BCP-ALL models, indicating it could be a promising option for relapsed and resistant patients.